Antitumor vaccines, immunotherapy and the immunological constant of rejection

E. Wang, A. Monaco, V. Monsurró, M. Sabatino, Z. Pos, L. Uccellini, J. Wang, A. Worschech, D. F. Stroncek, F. M. Marincola

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Anticancer vaccines have not matched the clinical expectations projected from their ability to induce consistently systemic anticancer T-cell responses. Thus, a dichotomy is observed between the immunological and clinical endpoints of anticancer immunization. Anticancer vaccines have clearly demonstrated that highly specific T-cell responses can be induced that can recognize autologous cancer antigens in patients with cancer. This ability is an outstanding achievement of modern biotechnology, yielding one of the most specific types of potential anticancer reagents. However, systemic, vaccine-induced anticancer responses exemplify a broader immunological paradox: cytotoxic T-cells can coexist within the same organism with their target cells not only in the context of cancer, but also in the context of chronic infections, well-controlled allo-transplant reactions and autoimmunity. According to this view, anticancer immune responses are a facet of a tissue-specific autoimmune phenomenon specific for cancer tissue that may or may not result in the successful immune-destruction of target cells, depending on an assortment of genetic factors related to the background of the host or evolving phenotypes of a heterogeneous cancer environment. This feature article summarizes the current understanding of the mechanisms leading to tumor rejection in humans as well as in experimental models, in the context of the broader immunological phenomenon leading to tissue-specific destruction. Anticancer vaccines that may not induce clinically significant anticancer responses independently could function as a unique tool to enhance the specificity of the response of the host against cancer, provided that strategies are implemented to amplify the immune reaction initiated by vaccine-induced antibodies and/or T-cells.

Original languageEnglish
Pages (from-to)297-301
Number of pages5
JournalIDrugs
Volume12
Issue number5
Publication statusPublished - May 2009
Externally publishedYes

Fingerprint

Immunotherapy
Vaccines
Neoplasms
T-Lymphocytes
Aptitude
Host Specificity
Autoantigens
Biotechnology
Rejection (Psychology)
Autoimmunity
Immunization
Theoretical Models
Transplants
Phenotype
Antibodies
Infection

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Wang, E., Monaco, A., Monsurró, V., Sabatino, M., Pos, Z., Uccellini, L., ... Marincola, F. M. (2009). Antitumor vaccines, immunotherapy and the immunological constant of rejection. IDrugs, 12(5), 297-301.

Antitumor vaccines, immunotherapy and the immunological constant of rejection. / Wang, E.; Monaco, A.; Monsurró, V.; Sabatino, M.; Pos, Z.; Uccellini, L.; Wang, J.; Worschech, A.; Stroncek, D. F.; Marincola, F. M.

In: IDrugs, Vol. 12, No. 5, 05.2009, p. 297-301.

Research output: Contribution to journalReview article

Wang, E, Monaco, A, Monsurró, V, Sabatino, M, Pos, Z, Uccellini, L, Wang, J, Worschech, A, Stroncek, DF & Marincola, FM 2009, 'Antitumor vaccines, immunotherapy and the immunological constant of rejection', IDrugs, vol. 12, no. 5, pp. 297-301.
Wang E, Monaco A, Monsurró V, Sabatino M, Pos Z, Uccellini L et al. Antitumor vaccines, immunotherapy and the immunological constant of rejection. IDrugs. 2009 May;12(5):297-301.
Wang, E. ; Monaco, A. ; Monsurró, V. ; Sabatino, M. ; Pos, Z. ; Uccellini, L. ; Wang, J. ; Worschech, A. ; Stroncek, D. F. ; Marincola, F. M. / Antitumor vaccines, immunotherapy and the immunological constant of rejection. In: IDrugs. 2009 ; Vol. 12, No. 5. pp. 297-301.
@article{0c1417e68cf44a75ab0af7c44f8e0a6f,
title = "Antitumor vaccines, immunotherapy and the immunological constant of rejection",
abstract = "Anticancer vaccines have not matched the clinical expectations projected from their ability to induce consistently systemic anticancer T-cell responses. Thus, a dichotomy is observed between the immunological and clinical endpoints of anticancer immunization. Anticancer vaccines have clearly demonstrated that highly specific T-cell responses can be induced that can recognize autologous cancer antigens in patients with cancer. This ability is an outstanding achievement of modern biotechnology, yielding one of the most specific types of potential anticancer reagents. However, systemic, vaccine-induced anticancer responses exemplify a broader immunological paradox: cytotoxic T-cells can coexist within the same organism with their target cells not only in the context of cancer, but also in the context of chronic infections, well-controlled allo-transplant reactions and autoimmunity. According to this view, anticancer immune responses are a facet of a tissue-specific autoimmune phenomenon specific for cancer tissue that may or may not result in the successful immune-destruction of target cells, depending on an assortment of genetic factors related to the background of the host or evolving phenotypes of a heterogeneous cancer environment. This feature article summarizes the current understanding of the mechanisms leading to tumor rejection in humans as well as in experimental models, in the context of the broader immunological phenomenon leading to tissue-specific destruction. Anticancer vaccines that may not induce clinically significant anticancer responses independently could function as a unique tool to enhance the specificity of the response of the host against cancer, provided that strategies are implemented to amplify the immune reaction initiated by vaccine-induced antibodies and/or T-cells.",
author = "E. Wang and A. Monaco and V. Monsurr{\'o} and M. Sabatino and Z. Pos and L. Uccellini and J. Wang and A. Worschech and Stroncek, {D. F.} and Marincola, {F. M.}",
year = "2009",
month = "5",
language = "English",
volume = "12",
pages = "297--301",
journal = "IDrugs : the investigational drugs journal",
issn = "1369-7056",
publisher = "Current Drugs Ltd.",
number = "5",

}

TY - JOUR

T1 - Antitumor vaccines, immunotherapy and the immunological constant of rejection

AU - Wang, E.

AU - Monaco, A.

AU - Monsurró, V.

AU - Sabatino, M.

AU - Pos, Z.

AU - Uccellini, L.

AU - Wang, J.

AU - Worschech, A.

AU - Stroncek, D. F.

AU - Marincola, F. M.

PY - 2009/5

Y1 - 2009/5

N2 - Anticancer vaccines have not matched the clinical expectations projected from their ability to induce consistently systemic anticancer T-cell responses. Thus, a dichotomy is observed between the immunological and clinical endpoints of anticancer immunization. Anticancer vaccines have clearly demonstrated that highly specific T-cell responses can be induced that can recognize autologous cancer antigens in patients with cancer. This ability is an outstanding achievement of modern biotechnology, yielding one of the most specific types of potential anticancer reagents. However, systemic, vaccine-induced anticancer responses exemplify a broader immunological paradox: cytotoxic T-cells can coexist within the same organism with their target cells not only in the context of cancer, but also in the context of chronic infections, well-controlled allo-transplant reactions and autoimmunity. According to this view, anticancer immune responses are a facet of a tissue-specific autoimmune phenomenon specific for cancer tissue that may or may not result in the successful immune-destruction of target cells, depending on an assortment of genetic factors related to the background of the host or evolving phenotypes of a heterogeneous cancer environment. This feature article summarizes the current understanding of the mechanisms leading to tumor rejection in humans as well as in experimental models, in the context of the broader immunological phenomenon leading to tissue-specific destruction. Anticancer vaccines that may not induce clinically significant anticancer responses independently could function as a unique tool to enhance the specificity of the response of the host against cancer, provided that strategies are implemented to amplify the immune reaction initiated by vaccine-induced antibodies and/or T-cells.

AB - Anticancer vaccines have not matched the clinical expectations projected from their ability to induce consistently systemic anticancer T-cell responses. Thus, a dichotomy is observed between the immunological and clinical endpoints of anticancer immunization. Anticancer vaccines have clearly demonstrated that highly specific T-cell responses can be induced that can recognize autologous cancer antigens in patients with cancer. This ability is an outstanding achievement of modern biotechnology, yielding one of the most specific types of potential anticancer reagents. However, systemic, vaccine-induced anticancer responses exemplify a broader immunological paradox: cytotoxic T-cells can coexist within the same organism with their target cells not only in the context of cancer, but also in the context of chronic infections, well-controlled allo-transplant reactions and autoimmunity. According to this view, anticancer immune responses are a facet of a tissue-specific autoimmune phenomenon specific for cancer tissue that may or may not result in the successful immune-destruction of target cells, depending on an assortment of genetic factors related to the background of the host or evolving phenotypes of a heterogeneous cancer environment. This feature article summarizes the current understanding of the mechanisms leading to tumor rejection in humans as well as in experimental models, in the context of the broader immunological phenomenon leading to tissue-specific destruction. Anticancer vaccines that may not induce clinically significant anticancer responses independently could function as a unique tool to enhance the specificity of the response of the host against cancer, provided that strategies are implemented to amplify the immune reaction initiated by vaccine-induced antibodies and/or T-cells.

UR - http://www.scopus.com/inward/record.url?scp=67649373099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649373099&partnerID=8YFLogxK

M3 - Review article

VL - 12

SP - 297

EP - 301

JO - IDrugs : the investigational drugs journal

JF - IDrugs : the investigational drugs journal

SN - 1369-7056

IS - 5

ER -